公开(公告)号：EP2012758A2

公开(公告)日：2009-01-14

申请号：EP07724232.9

申请日：2007-04-13

申请人： Sanofi-Aventis Deutschland GmbH

发明人： BRENDEL, Joachim ,  GOEGELEIN, Heinz ,  WIRTH, Klaus ,  KAMM, Walter

IPC分类号： A61K31/00 ,  A61K31/166 ,  A61K31/18 ,  A61K31/341 ,  A61K31/381 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/444 ,  A61K31/47

CPC分类号： A61K31/00 ,  A61K31/166 ,  A61K31/18 ,  A61K31/341 ,  A61K31/381 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/444 ,  A61K31/47

摘要： The invention relates to the use of Kv1.5 inhibitors for producing a medicament for the therapy or prophylaxis of respiratory disorders, sleep-related respiratory disorders, central and obstructive sleep apneas, upper airway reisistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, muscle-related respiratory disorders, respiratory disorders after long-term ventilation, respiratory disorders during adaptation in high mountains, acute and chronic lung disorders with hypoxia and hypercapnia, neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cancer disorders, breast cancer, lung cancer, colon cancer and prostate cancer.

摘要翻译： 本发明涉及Kv1.5抑制剂用于治疗或预防呼吸系统疾病，睡眠相关呼吸障碍，中枢性和阻塞性睡眠呼吸暂停，上呼吸道阻力综合征，Cheyne-Stokes呼吸，打鼾，中枢呼吸驱动中断，突发 儿童死亡，术后缺氧和呼吸暂停，肌肉相关呼吸障碍，长期通气后的呼吸系统疾病，高山适应期间的呼吸障碍，缺氧和高碳酸血症的急性和慢性肺病，神经退行性疾病，痴呆，阿尔茨海默病，帕金森病 ，亨廷顿舞蹈病，癌症疾病，乳腺癌，肺癌，结肠癌和前列腺癌。

公开(公告)号：EP1899320A1

公开(公告)日：2008-03-19

申请号：EP06754278.7

申请日：2006-06-10

申请人： Sanofi-Aventis

发明人： BRENDEL, Joachim ,  ENGLERT, Heinrich Christian ,  PEUKERT, Stefan ,  WIRTH, Klaus ,  WAGNER, Michael ,  RUXER, Jean-Marie ,  PILORGE, Fabienne

IPC分类号： C07D401/06 ,  C07D207/26 ,  C07D275/02 ,  C07D409/06 ,  C07D401/14 ,  C07D211/76 ,  A61K31/4015 ,  A61K31/4412 ,  A61P9/00 ,  A61P11/00 ,  A61P25/28 ,  A61P35/00

CPC分类号： C07D401/06 ,  C07D207/27 ,  C07D211/76 ,  C07D275/02 ,  C07D401/14 ,  C07D409/06

摘要： The invention relates to compounds of the formula (I), in which A, R1 , R2, R3, R4, R5, R6, R7 and n have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.

公开(公告)号：EP1385820B1

公开(公告)日：2011-10-12

申请号：EP02742898.6

申请日：2002-04-13

申请人： Sanofi-Aventis Deutschland GmbH

发明人： BRENDEL, Joachim ,  Dr. PIRARD, Bernard ,  PEUKERT, Stefan ,  KLEEMANN, Heinz-Werner ,  HEMMERLE, Horst

IPC分类号： C07C311/21 ,  C07C311/29 ,  C07D213/56 ,  C07C311/08 ,  C07D233/64 ,  C07D235/16 ,  C07D307/54 ,  C07D277/30 ,  C07D215/14 ,  C07D231/12 ,  A61K31/18

CPC分类号： C07D207/335 ,  C07C311/08 ,  C07C311/21 ,  C07C311/29 ,  C07C311/44 ,  C07C2601/02 ,  C07C2601/14 ,  C07D213/40 ,  C07D213/64 ,  C07D215/12 ,  C07D231/12 ,  C07D231/16 ,  C07D233/56 ,  C07D233/64 ,  C07D235/14 ,  C07D249/08 ,  C07D277/28 ,  C07D307/14 ,  C07D307/52 ,  C07D405/12

摘要： The invention relates to anthranilic acid amides, to a method for the production thereof, to their use as a medicament, and to pharmaceutical preparations containing these anthranilic acid amides. The anthranilic acid amides consist of compounds of formula (I) in which R(1) to (R7) have the meanings as cited in the claims, act upon the Kv1.5 potassium channel, and inhibit a potassium stream described as an 'ultra-rapidly activating delayed rectifier' in the human cardiac atrium. The compounds are therefore especially suited as novel antiarrhythmic active substances, particularly for treating and preventing atrial arrhythmias, e.g. atrial fibrillation AF or atrial flutter.

公开(公告)号：EP1399423B9

公开(公告)日：2008-02-27

申请号：EP02745333.1

申请日：2002-05-31

申请人： Sanofi-Aventis Deutschland GmbH

发明人： BRENDEL, Joachim ,  BÖHME, Thomas ,  PEUKERT, Stefan ,  KLEEMANN, Heinz-Werner

IPC分类号： C07D215/36 ,  A61K31/33 ,  A61P9/06 ,  C07D401/12 ,  C07D333/34 ,  C07D405/12 ,  C07D261/10 ,  C07D271/12 ,  C07D213/71

CPC分类号： C07D261/10 ,  A61K31/47 ,  A61K45/06 ,  C07D215/36 ,  C07D217/02 ,  C07D271/12 ,  C07D333/34 ,  C07D401/12 ,  C07D405/12 ,  A61K2300/00

摘要： The invention relates to compounds of formula (I), wherein R(1) -R(7) have the meanings cited in the claims. Said compounds act upon the Kv1.5-potassium channel and inhibit a potassium flow in the atrium of the human heart, designated as an ultra-rapidly activating delayed rectifier. As a result, they are particularly suitable for use as novel antiarrhythmic active substances, especially in the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter.

公开(公告)号：EP2125745A1

公开(公告)日：2009-12-02

申请号：EP07856887.0

申请日：2007-12-19

申请人： Sanofi-Aventis

发明人： PLETTENBURG, Oliver ,  HOFMEISTER, Armin ,  LORENZ, Katrin ,  BRENDEL, Joachim ,  LÖHN, Matthias ,  WESTON, John

IPC分类号： C07D217/24 ,  C07D401/12 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/5377

CPC分类号： C07D217/24 ,  C07D401/12

摘要： The invention relates to 6-substituted isoquinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

摘要翻译： 本发明涉及可用于治疗和/或预防与肌球蛋白轻链磷酸酶的Rho-激酶和/或Rho-激酶介导的磷酸化有关的疾病的式（I）的6-取代的异喹诺酮衍生物和含有这些化合物的组合物。

公开(公告)号：EP1912949A1

公开(公告)日：2008-04-23

申请号：EP06776307.8

申请日：2006-07-20

申请人： Sanofi-Aventis

发明人： PLETTENBURG, Oliver ,  HOFMEISTER, Armin ,  KADEREIT, Dieter ,  BRENDEL, Joachim ,  LOEHN, Matthias

IPC分类号： C07D217/24 ,  A61K31/472 ,  A61P9/12

CPC分类号： C07D217/24 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12

摘要： The invention relates to 6-cyclohexylamine-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I’) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

公开(公告)号：EP1910333A1

公开(公告)日：2008-04-16

申请号：EP06776306.0

申请日：2006-07-20

申请人： Sanofi-Aventis

发明人： PLETTENBURG, Oliver ,  HOFMEISTER, Armin ,  KADEREIT, Dieter ,  BRENDEL, Joachim ,  LOEHN, Matthias

IPC分类号： C07D401/12 ,  A61K31/4725 ,  A61P9/12

CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14

摘要： The invention relates to 6-piperidinyl-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I´) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

摘要翻译： 本发明涉及用于治疗和/或预防与Rho-激酶和/或Rho-激酶介导的磷酸化相关的疾病的式（I）的6-哌啶基 - 取代的异喹诺酮衍生物或式（I'）的异喹啉衍生物 肌球蛋白轻链磷酸酶，以及含有这些化合物的组合物。

公开(公告)号：EP1896416A1

公开(公告)日：2008-03-12

申请号：EP06754277.9

申请日：2006-06-10

申请人： sanofi-aventis

发明人： BRENDEL, Joachim ,  ENGLERT, Heinrich, Christian ,  WIRTH, Klaus ,  WAGNER, Michael ,  RUXER, Jean-Marie c/o Aventis Pharma ,  PILORGE, Fabienne c/o Aventis Pharma

IPC分类号： C07D213/64 ,  C07D237/14 ,  A61K31/4412 ,  A61K31/50 ,  A61P9/00 ,  A61P11/00 ,  A61P25/00 ,  A61P35/00

CPC分类号： C07D213/64 ,  C07D237/14

摘要： The invention relates to compounds of the formula (I), in which R1 , R2, R3, R4, R5, R6 and X have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.

公开(公告)号：EP1399423B1

公开(公告)日：2007-11-14

申请号：EP02745333.1

申请日：2002-05-31

申请人： Sanofi-Aventis Deutschland GmbH

发明人： BRENDEL, Joachim ,  BÖHME, Thomas ,  PEUKERT, Stefan ,  KLEEMANN, Heinz-Werner

IPC分类号： C07D215/36 ,  A61K31/33 ,  A61P9/06 ,  C07D401/12 ,  C07D333/34 ,  C07D405/12 ,  C07D261/10 ,  C07D271/12 ,  C07D213/71

CPC分类号： C07D261/10 ,  A61K31/47 ,  A61K45/06 ,  C07D215/36 ,  C07D217/02 ,  C07D271/12 ,  C07D333/34 ,  C07D401/12 ,  C07D405/12 ,  A61K2300/00

摘要： The invention relates to compounds of formula (I), wherein R(1) -R(7) have the meanings cited in the claims. Said compounds act upon the Kv1.5-potassium channel and inhibit a potassium flow in the atrium of the human heart, designated as an ultra-rapidly activating delayed rectifier. As a result, they are particularly suitable for use as novel antiarrhythmic active substances, especially in the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter.

公开(公告)号：EP1899320B1

公开(公告)日：2010-10-20

申请号：EP06754278.7

申请日：2006-06-10

申请人： Sanofi-Aventis

发明人： BRENDEL, Joachim ,  ENGLERT, Heinrich Christian ,  PEUKERT, Stefan ,  WIRTH, Klaus ,  WAGNER, Michael ,  RUXER, Jean-Marie ,  PILORGE, Fabienne

IPC分类号： C07D401/06 ,  C07D207/26 ,  C07D275/02 ,  C07D409/06 ,  C07D401/14 ,  C07D211/76 ,  A61K31/4015 ,  A61K31/4412 ,  A61P9/00 ,  A61P11/00 ,  A61P25/28 ,  A61P35/00

CPC分类号： C07D401/06 ,  C07D207/27 ,  C07D211/76 ,  C07D275/02 ,  C07D401/14 ,  C07D409/06

摘要： The invention relates to compounds of the formula (I), in which A, R1 , R2, R3, R4, R5, R6, R7 and n have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.